Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients

被引：0
|
作者：
Zhang, H. [1 ]
Cun, F. S. [1 ]
机构：
[1] Nanjing Chest Hosp, Resp Med, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S1586 / S1587
页数：2
相关论文
共 50 条
  • [1] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
    Fang, S.
    Xu, T.
    Zhao, X.
    Liu, N.
    Wang, X.
    Cheng, W.
    Fang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
  • [2] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
  • [3] First-line and beyond: West Midlands real-world data for EGFR mutant (EGFRm) NSCLC
    Powell, R.
    Kussaibati, R.
    Khan, A.
    Sivapalasuntharam, A.
    Wilson, P.
    Chowdhary, R.
    Murukesh, N.
    Jain, A.
    Iqbal, M.
    Ghafoor, Q.
    Baijal, S.
    LUNG CANCER, 2020, 139 : S60 - S61
  • [4] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [5] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
  • [6] Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
    Duan, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [7] Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
    Russano, M.
    Cantini, L.
    B, A. P.
    George, R.
    Nunes, P.
    Tolba, K.
    Dutra, C.
    Chico, I.
    Cortellini, A.
    Pecci, F.
    Alessi, J. V.
    Ricciuti, B.
    Ramkissoon, S.
    Aerts, J. G.
    Agrawal, S.
    Saini, K. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S854 - S854
  • [8] LTreatment sequencing in NSCLC EGFR plus - real-world data
    Fernandes, Ana Luisa
    Dias, Margarida
    Coutinho, Daniel
    Silva, Eloisa
    Costa, Telma
    Campainha, Sergio
    Conde, Sara
    Barroso, Ana
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [9] Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
    Lee, J. Y.
    Mai, V.
    Garcia, M.
    Cheng, S.
    Khan, K.
    Balaratnam, K.
    Thakral, A.
    Brown, M. C.
    Zhan, L.
    Corke, L.
    Leighl, N.
    Shepherd, F. A.
    Bradbury, P.
    Sacher, A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S440 - S440
  • [10] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Lu, Shun
    Shih, Jin-Yuan
    Jang, Tae-Won
    Liam, Chong-Kin
    Yu, Yongfeng
    ADVANCES IN THERAPY, 2021, 38 (05) : 2038 - 2053
12345